At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RGLS Regulus Therapeutics
Closed 05-15 16:00:00 EDT
2.02
-0.06
-2.88%
盘后2.02
+0.000.00%
19:24 EDT
High2.13
Low1.94
Vol605.59K
Open2.09
D1 Closing2.08
Amplitude9.13%
Mkt Cap132.24M
Tradable Cap83.93M
Total Shares65.47M
T/O1.22M
T/O Rate1.46%
Tradable Shares41.55M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.